The sustained virologic response of nonresponder hepatitis C virus patients with retreatment

Indian Journal of Pathology and Microbiology

Volumn 54, Issue 1, 2011, Pages 81-84

  Akhan, Sila Cetin ^a   Gurel, Erdem ^a   Sayan, Murat ^b  

^a KOCAELI UNIVERSITY   (Turkey)

^b Polymerase Chain Reaction Unit   (Turkey)

Author keywords

Hepatitis C virus; pegylated interferon; retreatment

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79952967984     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.77330     Document Type: Article

References (17)

1. Yoshida EM, Sherman M, Bain VG, Cooper CL, Deschênes M, Marotta PJ, et al. Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol 2009;23:180-4.
2. Gambarin-Gelwan M, Jacobson IM. Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C. J Viral Hepat 2008;15:623-33.
3. Chayama K. Genotyping Hepatitis C Virus by Type Specific Primers for PCR Based on NS5 Region. Totowa, NJ: Humana Press; 1998.
4. Akhan SC, Kalender B, Ruzgar M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection 2008;36:341-4.
5. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão- Mello CE, et al. Retreatmentof patients with chronic hepatitis C who do not respond to peginterferonalpha2b: A randomized trial. Ann Intern Med 2009;150:528-40.
6. Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, et al. Peginterferon alpha-2a and ribavirin versus peginterferon alpha- 2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: The SMIEC II trial in naïve patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2008;20:680-7.
7. Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rakela J, Balan V. Pegylated interferon and ribavirin failures: Is retreatment an option?. Dig Dis Sci 2007;52:732-6.
8. Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005;100:2453-62.
9. Poordad FF, Flamm SL. Virological relapse in chronic hepatitis C. Antivir Ther 2009;14:303-13.
10. Lee SS, Abdo AA. Predicting antiviral treatment response in chronic hepatitis C: How accurate and how soon?. J Antimicrob Chemother 2003;51:487-91. (Pubitemid 36336140)
11. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
12. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
13. Krawitt EL, Ashikaga T, Gordon SR, Ferrentino N, Ray MA, Lidofsky SD. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005;43:243-9. (Pubitemid 40956876)
14. Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, et al. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy. Braz J Infect Dis 2006;10:11-6. (Pubitemid 43881087)
15. Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006;55:1631-8. (Pubitemid 44629215)
16. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: Effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009;136:1618-28.
17. Berg C, Goncales FL Jr, Bernstein DE, Sette H Jr, Rasenack J, Diago M, et al. Re-treatment of chronic hepatitis C patients after relapse: Efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepat 2006;13:435-40.